This second milestone related to the start of the Fentanyl Taifun Phase III program should be followed within the next quarter by the enrollment of the first patients in Phase III efficacy and safety studies in Europe.
Janssen Pharmaceutica is the licensee for the product in Europe, Canada, Middle East and Africa.